Trials / Completed
CompletedNCT00482430
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and effectiveness of an investigational drug for the treatment of cognitive impairment in patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0557 | MK0557 10mg tablet qd for a 15-wk treatment period |
| DRUG | Comparator: Placebo (unspecified) | MK0557 Pbo tablet qd for a 15-wk treatment period |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2007-06-05
- Last updated
- 2015-08-21
Source: ClinicalTrials.gov record NCT00482430. Inclusion in this directory is not an endorsement.